-
公开(公告)号：US11559521B2
公开(公告)日：2023-01-24
申请号：US16834863
申请日：2020-03-30
IPC分类号： A61K31/135 , A61P23/02 , A61K31/445 , A61M25/00 , A61K31/407 , A61P29/00
摘要： A multimodal anti-emetic anesthetic/analgesic formulation for pain control not limited to postoperative pain control is described herein. The opioid-free/sparing anesthetic/analgesic formulation comprises a local anesthetic, an N-methyl-D-aspartate (NMDA) receptor antagonist, and a cyclooxygenase (COX) inhibitor such as Bupivacaine Hydrochloride, Ketamine Hydrochloride, and Ketorolac Tromethamine, which is effective to significantly reduce postoperative nausea and vomiting and enhance postoperative pain relief as compared to existing prior art anesthetics/analgesics. The formulation is administered to a mammal in need of anesthesia/analgesia and can be used as a preemptive and preventative multimodal analgesic. The formulation may have a buffer to enhance its shelf life and improve pharmacokinetics. The formulation may further comprise an alpha agonist, a steroid, a Transient Receptor Potential Channel agonist or antagonist, a beta-lactam antibiotic, a protein kinase inhibitor, a competitive or non-competitive glycine or glutamate antagonist, a glutamate or glycine inhibitor, a cyclooxygenase 3 inhibitor, or combinations thereof.
-
2.发明申请公开(公告)号：US20200230120A1
公开(公告)日：2020-07-23
申请号：US16834863
申请日：2020-03-30
IPC分类号： A61K31/445 , A61K31/135 , A61K31/407 , A61M25/00
摘要： A multimodal anti-emetic anesthetic/analgesic formulation for pain control not limited to postoperative pain control is described herein. The opioid-free/sparing anesthetic/analgesic formulation comprises a local anesthetic, an N-methyl-D-aspartate (NMDA) receptor antagonist, and a cyclooxygenase (COX) inhibitor such as Bupivacaine Hydrochloride, Ketamine Hydrochloride, and Ketorolac Tromethamine, which is effective to significantly reduce postoperative nausea and vomiting and enhance postoperative pain relief as compared to existing prior art anesthetics/analgesics. The formulation is administered to a mammal in need of anesthesia/analgesia and can be used as a preemptive and preventative multimodal analgesic. The formulation may have a buffer to enhance its shelf life and improve pharmacokinetics. The formulation may further comprise an alpha agonist, a steroid, a Transient Receptor Potential Channel agonist or antagonist, a beta-lactam antibiotic, a protein kinase inhibitor, a competitive or non-competitive glycine or glutamate antagonist, a glutamate or glycine inhibitor, a cyclooxygenase 3 inhibitor, or combinations thereof.
-
公开(公告)号：US10098872B1
公开(公告)日：2018-10-16
申请号：US14997046
申请日：2016-01-15
IPC分类号： A61K31/445 , A61K31/135 , A61K31/407 , A61M5/14 , A61M5/142 , A61M25/00
摘要： The present invention is an analgesic for pain control not limited to postoperative pain control. The present invention discloses an opioid sparing anesthetic formulation comprising a local anesthetic, an N-methyl-D-aspartate (NMDA) receptor antagonist, and a cyclooxygenase (COX) inhibitor such as Bupivacaine, Ketamine, and Ketorolac, which is effective to significantly reduce postoperative nausea and vomiting and enhance postoperative pain relief as compared to existing prior art anesthetics. The formulation is administered to a mammal in need of pain treatment. The formulation may be used as a preemptive analgesic. The analgesic formulation has a buffer for enhancing its shelf life.
-
-
搜索结果
3 条记录 (耗时 0.01 秒)
